Masaki Kato

34PUBLICATIONS
86CO-AUTHORS
Psychological methodology, design and analysisPharmacogenomicsMemory and attentionTraditional Chinese medicine and treatmentsToxicology (incl. clinical toxicology)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (34)

|Jul 28, 2026
Adjunctive Pharmacotherapy for Major Depressive Disorder with Anxiety Symptoms: from Monoamines to Recent Clinical Evidence.

|Jun 03, 2026
Real-World Vortioxetine Prescription for Patients With Major Depressive Disorder in Japan: A Retrospective Cohort Study Using a Japanese Health Insurance Claims Database.

|Apr 26, 2026
Reduced pre-treatment isolated effective coherence between the dorsolateral prefrontal cortex and the subgenual anterior cingulate cortex as a potential predictive marker for remission following repetitive transcranial magnetic stimulation in major depressive disorder.

|Feb 23, 2026
Safety and efficacy of zuranolone in Japanese adults with major depressive disorder: An open-label, repeated-treatment part of a Phase 3 clinical trial.

Masaki Kato, Kazuyuki Nakagome, Takamichi Baba

|Dec 04, 2025
A 12-Week, Open-Label, Multicenter Pilot Study to Evaluate the Efficacy and Safety of Lemborexant in Patients with Insomnia Comorbid with Depressive Episodes (SELENADE).

Yoshikazu Takaesu, Hiroyuki Muraoka, Masahiro Takeshima

|Nov 18, 2025
Efficacy and safety of zuranolone in Japanese adults with major depressive disorder: A double-blind, randomized, placebo-controlled, Phase 3 clinical trial.

Masaki Kato, Kazuyuki Nakagome, Takamichi Baba

Pageof 6

Frequent Collaborators

7 joint publications

Koichiro Watanabe

7 joint publications

Yoshiteru Takekita

5 joint publications

Taro Kishi

4 joint publications

Takashi Tsuboi